Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
CytomX Therapeutics ( (CTMX) ) just unveiled an update.
On May 12, 2025, CytomX Therapeutics entered into an underwriting agreement with Jefferies LLC and Piper Sandler & Co. for the sale of 76,923,076 shares of common stock at $1.30 per share, resulting in estimated net proceeds of $93.4 million. The funds are intended for research and development, general corporate purposes, and working capital needs, potentially strengthening CytomX’s position in the biotechnology sector.
The most recent analyst rating on (CTMX) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on CytomX Therapeutics stock, see the CTMX Stock Forecast page.
Spark’s Take on CTMX Stock
According to Spark, TipRanks’ AI Analyst, CTMX is a Neutral.
CytomX Therapeutics presents a mixed investment case. Strong revenue growth and positive technical momentum are encouraging, and the low P/E ratio suggests potential undervaluation. However, significant risks stem from the negative equity position and cash flow challenges, which could impact long-term sustainability. The earnings call and recent corporate event provide optimism through advancing clinical programs, but financial health concerns weigh on the overall outlook.
To see Spark’s full report on CTMX stock, click here.
More about CytomX Therapeutics
CytomX Therapeutics operates in the biotechnology industry, focusing on the development of innovative therapies. The company is primarily engaged in research and development activities aimed at creating novel cancer treatments.
Average Trading Volume: 4,308,232
Technical Sentiment Signal: Buy
Current Market Cap: $171.7M
For detailed information about CTMX stock, go to TipRanks’ Stock Analysis page.